Gen-Probe Announces Webcast of Third Quarter 2003 Earnings Conference Call
SAN DIEGO, Oct 16, 2003 (BUSINESS WIRE) -- Gen-Probe Incorporated (Nasdaq:GPRO) today announced that it will release its third quarter 2003 financial results on Thursday, October 30, 2003 at 4:00 p.m. Eastern Standard Time (EST). The announcement will be followed by a conference call at 4:30 p.m. ET hosted by Henry L. Nordhoff, chairman, president and CEO and Herm Rosenman, Vice President, Finance and CFO.
The conference call will be webcast live and may be accessed on the Company's web site at www.gen-probe.com. Following the conference call, an archived version of the webcast will be available on the same web site until November 28, 2003. A replay will also be available until November 5, 2003. To access the replay, please call 1-800-294-4341 (U.S.) or 402-220-9773 (international).
About Gen-Probe Incorporated
Gen-Probe Incorporated, founded in 1983, is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid testing products used for the clinical diagnosis of human diseases and for screening donated human blood. Using its patented NAT technology, Gen-Probe has received FDA approvals or clearances for more than 60 products that detect a wide variety of infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections. Additionally, the Company developed and manufactures the only FDA-approved blood screening assay for the simultaneous detection of HIV-1 and HCV, which is marketed by Chiron Corporation. Gen-Probe and Bayer Corporation have formed a collaboration to develop, manufacture and market nucleic acid diagnostic tests for certain viral organisms, and under the agreement Bayer has the right to distribute these tests, including the recently approved VERSANT(R) HCV Qualitative Assay. Gen-Probe has 20 years of nucleic acid detection research and product development experience, and its products are used daily in clinical laboratories and blood collection centers throughout the world. Gen-Probe is headquartered in San Diego, California and has approximately 700 employees. Additional information about the Company can be found on the Internet at www.gen-probe.com. VERSANT is a trademark of Bayer Corporation.
Any statements in this news release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those relating to the use and effectiveness of our products and our collaborations and other agreements with third parties to develop, manufacture and market our products are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Factors that may cause such a difference include but are not limited to the success of our collaborations with third parties and fluctuations in our quarterly revenue and operating results. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our registration statement on Form S-3 that we filed on August 29, 2003 and all our periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE: Gen-Probe Incorporated
Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page.